<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01144143</url>
  </required_header>
  <id_info>
    <org_study_id>10702</org_study_id>
    <nct_id>NCT01144143</nct_id>
  </id_info>
  <brief_title>Treatment Of Knee Osteoarthritis With Intra-Articular Infliximab</brief_title>
  <official_title>Single Center, Randomized, Double-Blind, Placebo-Controlled Treatment Of Knee Osteoarthritis With Intra-Articular Infliximab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herbert Lindsley, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centocor, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if an anti-inflammatory drug, called infliximab,
      will reduce inflammation in the synovial lining in patients with an early stage of
      osteoarthritis of the knee. It will also help determine if the study medication decreases the
      accumulation of synovial fluid and prevents cartilage breakdown.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an unbalanced randomized, double-blind pilot study of Infliximab (100 mg), placebo
      (100 mg) and Methylprednisolone acetate (80 mg). A total of 16 subjects will be randomized; 8
      subjects will be randomized to receive infliximab, 4 subjects will be randomized to receive
      placebo and 4 additional subjects will be randomized to receive Methylprednisolone acetate.
      Subjects will be seen at screening, day 0, day 14, day 28 and day 56. After study drug
      injection at day 0, patients will return for follow-up visits at approximately 2 weeks, 1 and
      2 months in order to obtain clinical endpoint measures for a total of 10 weeks. Outcome
      measures include blood tests, MRI, ultrasound, synovial lining tissue biopsy questionnaires
      and adverse events.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Cellular Infiltrates From Day 0 to Day 28</measure>
    <time_frame>Day 0 to Day 28</time_frame>
    <description>Cellular infiltration scored 0 to 3</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Joint Effusions From Day 0 to Day 56 Target Knee</measure>
    <time_frame>Change from Day 0 to Day 56</time_frame>
    <description>Outcome calculated based on Physician observation of joint swelling from 0-3. A score of 0 = no effusion,1 = positive &quot;bulge,&quot; 2 = moderate effusion, 3 = tense effusion. The outcome represents the change in means between the two time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Western Ontario and McMaster Universities Arthritis Index (WOMAC) Score Target Knee</measure>
    <time_frame>Change from Day 0 to Day 56</time_frame>
    <description>The WOMAC questionnaire is used to evaluate the condition of patients with osteoarthritis. Patients answer questions based on how they are feeling. The questionnaire has a total of 24 questions which deal with pain, stiffness and physical function. Participants are asked to respond to how difficult it is for them to do/complete an activity. There is a total possible score of 96. A score of 0 equals no difficulty completing any of the 24 activities. A score of 96 would indicate extreme difficulty with all activities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Levels of Serum IL-6</measure>
    <time_frame>Change from Day 0 to Day 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum CRP Day 0 to Day 56</measure>
    <time_frame>Day 0 to Day 56</time_frame>
    <description>Serum measure of systemic inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum SAA Levels Day 0 to Day 56</measure>
    <time_frame>Day 0 to Day 56</time_frame>
    <description>Serum Amyloid A</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Osteoarthritis of the Knee</condition>
  <arm_group>
    <arm_group_label>Infliximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Salt Water</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Methylprednisolone acetate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infliximab</intervention_name>
    <description>the study drug will be injected into the joint through a needle</description>
    <arm_group_label>Infliximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>the placebo will be injected into the joint through a needle</description>
    <arm_group_label>Salt Water</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of Care: Methylprednisolone acetate</intervention_name>
    <description>Methylprednisolone acetate will be injected into the joint through a needle</description>
    <arm_group_label>Methylprednisolone acetate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adults ≥ age 35 but ≤ age 85.

          2. Painful knees for 3-60 months.

          3. VAS joint pain score greater than 30 mm (scale 0-100)

          4. Knee radiograph showing minimal to moderate change (early OA).

          5. No NSAID therapy for at least one week.

          6. Have the capacity to understand and sign an informed consent form.

          7. Gender: Male or female

          8. Women must be postmenopausal (no menstrual period for a minimum of 1 year) or
             surgically sterilized and have a negative serum pregnancy test on entry in the study.
             Men must agree to use adequate birth control during the study for 6 months after the
             infusion of study agent.

          9. Men and women of childbearing potential must use adequate birth control measures
             (e.g., abstinence, oral contraceptives, intrauterine device, barrier method with
             spermicide, implantable or injectable contraceptives or surgical sterilization) for
             the duration of the study and should continue such precautions for 6 months after
             receiving the last infusion.

         10. The screening laboratory test results must meet the following criteria

               1. WBC (white blood cell count): &gt;3.5/uL

               2. Hemoglobin: &gt; 10 gm/dl

               3. Platelets: &gt; 100,000/ul

               4. Serum Creatinine: &lt; 1.8

               5. SGPT (ALT - alanine aminotransferase) &lt;3 times ULN

               6. UA (urinalysis) with microscopic exam: WNL

               7. Negative tests for HbsAg or hepatitis C Ab

               8. PT/PTT: WNL

         11. Are considered eligible according to the following TB screening criteria:

               1. Have no history of latent or active TB prior to screening. An exception is made
                  for subjects who have a history of latent TB (defined for the purposes of this
                  study as having had a positive result from either the tuberculin skin test or the
                  QuantiFERON-TB Gold test prior to screening) and documentation of having
                  completed an adequate treatment regimen for latent TB within 3 years prior to the
                  first administration of study agent under this protocol. Adequate treatment for
                  latent TB is defined according to local country guidelines for immunocompromised
                  patients. If no local guidelines for immunocompromised patients exist, US
                  guidelines must be followed. It is the responsibility of the investigator to
                  verify the adequacy of previous anti-TB treatment and provide appropriate
                  documentation.

               2. Have no signs or symptoms suggestive of active TB upon medical history and/or
                  physical examination.

               3. Have had no recent close contact with a person with active TB or, if there has
                  been such contact, will be referred to a physician specializing in TB to undergo
                  additional evaluation and, if warranted, receive appropriate treatment for latent
                  TB prior to or simultaneously with the first administration of study agent.

               4. Within 1 month prior to the first administration of study agent, either have
                  negative diagnostic TB test results (defined as both a negative tuberculin skin
                  test and a negative QuantiFERON-TB Gold test, as outlined in Attachment 3 and
                  Attachment 4, respectively), or have a newly identified positive diagnostic TB
                  test result (defined as either a positive tuberculin skin test or a positive
                  QuantiFERON-TB Gold test) during screening in which active TB has been ruled out
                  and for which appropriate treatment for latent TB has been initiated either prior
                  to or simultaneously with the first administration of study agent. The tuberculin
                  skin test and QuantiFERON-TB Gold test are not required at screening for subjects
                  with a history of latent TB and documentation of having completed adequate
                  treatment as described in Inclusion Criterion 12a. Furthermore, these subjects
                  are not required to initiate additional treatment for latent TB.

               5. Have a chest radiograph (both posterior-anterior and lateral views), taken within
                  3 months prior to the first administration of study agent and read by a qualified
                  radiologist, with no evidence of current active TB or old inactive TB.

        Exclusion Criteria:

          1. Moderate to Severe OA, as determined by severe joint space narrowing (Kellgren grade
             IV) (7) in medial and lateral compartments

          2. Insulin-dependent diabetes mellitus.

          3. Systemic inflammatory illness, e.g. rheumatoid arthritis.

          4. Intra-articular injections within 3 months.

          5. Prior treatment with infliximab or other anti-TNF drug.

          6. Acute injury to knees (&lt; 2 weeks)

          7. Women who are pregnant, nursing, or planning pregnancy within 6 months after the last
             infusion (this includes father's who plan on fathering a child within 6 months after
             their last infusion).

          8. Have had any previous treatment with monoclonal antibodies or antibody fragments.

          9. History of receiving human/murine recombinant products or a known allergy to murine
             products. A known allergy to murine product is definitely an exclusion criterion

         10. Documentation of a positive test for hepatitis B surface antigen or hepatitis C.

         11. Have a history of alcohol or substance abuse within the preceding 6 months that, in
             the opinion of the investigator, may increase the risks associated with study
             participation or study agent administration, or may interfere with interpretation of
             results.

         12. Have a known history of serious infections (e.g., hepatitis, pneumonia, or
             pyelonephritis) in the previous 3 months.

         13. Have or have had an opportunistic infection (e.g., herpes zoster [shingles],
             cytomegalovirus, Pneumocystis carinii, aspergillosis, histoplasmosis, or mycobacteria
             other than TB) within 6 months prior to screening

         14. Currently receiving Coumadin, Ticlid, Plavix, or heparin/heparin analog within 7 days
             prior to synovial biopsy.

         15. Currently receiving aspirin within 7 days prior to synovial biopsy.

         16. Have a chest radiograph at screening that shows evidence of malignancy or infection.

         17. Have a history of lymphoproliferative disease, including lymphoma or signs suggestive
             of possible lymphoproliferative disease such as lymphadenopathy of unusual size or
             location (e.g., nodes in the posterior triangle of the neck, infraclavicular,
             epitrochlear, or periaortic area), or splenomegaly.

         18. Currently have any known malignancy or have a history of malignancy within the
             previous 5 years, with the exception of basal cell or squamous cell carcinoma of the
             skin that has been fully excised with no evidence of recurrence as well as carcinoma
             in situ of the cervix.

         19. Have current signs or symptoms of severe, progressive or uncontrolled renal, hepatic,
             hematologic, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, or cerebral
             disease.

         20. Are unable or unwilling to undergo multiple venipunctures because of poor tolerability
             or lack of easy access.

         21. Use of any investigational drug within 30 days prior to screening or within 5
             half-lives of the investigational agent, whichever is longer.

         22. Presence of a transplanted solid organ (with the exception of a corneal transplant &gt; 3
             months prior to screening).

         23. Have a concomitant diagnosis or history of congestive heart failure Grade III-IV.

         24. Have had a nontuberculous mycobacterial infection or opportunistic infection (e.g.,
             cytomegalovirus, Pneumocystis carinii, and aspergillosis) within 6 months prior to
             screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Herbert Lindsley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2010</study_first_submitted>
  <study_first_submitted_qc>June 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2010</study_first_posted>
  <results_first_submitted>April 21, 2017</results_first_submitted>
  <results_first_submitted_qc>January 12, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 8, 2018</results_first_posted>
  <last_update_submitted>January 12, 2018</last_update_submitted>
  <last_update_submitted_qc>January 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kansas Medical Center</investigator_affiliation>
    <investigator_full_name>Herbert Lindsley, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Mild to moderate osteoarthritis of the knee</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Infliximab</title>
          <description>Investigational (Infliximab) – 100mg The study drug will be injected into the joint through a needle</description>
        </group>
        <group group_id="P2">
          <title>Salt Water</title>
          <description>Placebo (Salt Water) – 10 ml Placebo solution will be injected into the joint through a needle</description>
        </group>
        <group group_id="P3">
          <title>Methylprednisolone Acetate</title>
          <description>Methylprednisolone Acetate (Standard of Care: MPA) – Standard of Care: MPA 80mg injected into the joint through a needle</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Infliximab</title>
          <description>Investigational (Infliximab) – 100mg The study drug will be injected into the joint through a needle</description>
        </group>
        <group group_id="B2">
          <title>Salt Water</title>
          <description>Placebo (Salt Water) – 10 ml Placebo solution will be injected into the joint through a needle</description>
        </group>
        <group group_id="B3">
          <title>Methylprednisolone Acetate</title>
          <description>Methylprednisolone Acetate (Standard of Care: MPA) – Standard of Care: MPA 80mg injected into the joint through a needle</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Number</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Cellular Infiltrates From Day 0 to Day 28</title>
        <description>Cellular infiltration scored 0 to 3</description>
        <time_frame>Day 0 to Day 28</time_frame>
        <population>In the MPA arm, one subject was excluded from the analysis because their biopsy sample was of insufficient quantity to be processed in the lab.</population>
        <group_list>
          <group group_id="O1">
            <title>Infliximab</title>
            <description>Investigational (Infliximab) – 100mg The study drug will be injected into the joint through a needle</description>
          </group>
          <group group_id="O2">
            <title>Salt Water</title>
            <description>Placebo (Salt Water) – 10 ml Placebo solution will be injected into the joint through a needle</description>
          </group>
          <group group_id="O3">
            <title>Methylprednisolone Acetate</title>
            <description>Methylprednisolone Acetate (Standard of Care: MPA) – Standard of Care: MPA 80mg injected into the joint through a needle</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cellular Infiltrates From Day 0 to Day 28</title>
          <description>Cellular infiltration scored 0 to 3</description>
          <population>In the MPA arm, one subject was excluded from the analysis because their biopsy sample was of insufficient quantity to be processed in the lab.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Decreased cellularity</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increased cellularity</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unchanged cellularity</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Joint Effusions From Day 0 to Day 56 Target Knee</title>
        <description>Outcome calculated based on Physician observation of joint swelling from 0-3. A score of 0 = no effusion,1 = positive “bulge,” 2 = moderate effusion, 3 = tense effusion. The outcome represents the change in means between the two time points.</description>
        <time_frame>Change from Day 0 to Day 56</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Infliximab</title>
            <description>Investigational (Infliximab) – 100mg The study drug will be injected into the joint through a needle</description>
          </group>
          <group group_id="O2">
            <title>Salt Water</title>
            <description>Placebo (Salt Water) – 10 ml Placebo solution will be injected into the joint through a needlePlacebo: the placebo will be injected into the joint through a needle</description>
          </group>
          <group group_id="O3">
            <title>Methylprednisolone Acetate</title>
            <description>Methylprednisolone Acetate (Standard of Care: MPA) – Standard of Care: MPA 80mg injected into the joint through a needle</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Joint Effusions From Day 0 to Day 56 Target Knee</title>
          <description>Outcome calculated based on Physician observation of joint swelling from 0-3. A score of 0 = no effusion,1 = positive “bulge,” 2 = moderate effusion, 3 = tense effusion. The outcome represents the change in means between the two time points.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.5"/>
                    <measurement group_id="O2" value="0.0" spread="0.0"/>
                    <measurement group_id="O3" value="0.0" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Western Ontario and McMaster Universities Arthritis Index (WOMAC) Score Target Knee</title>
        <description>The WOMAC questionnaire is used to evaluate the condition of patients with osteoarthritis. Patients answer questions based on how they are feeling. The questionnaire has a total of 24 questions which deal with pain, stiffness and physical function. Participants are asked to respond to how difficult it is for them to do/complete an activity. There is a total possible score of 96. A score of 0 equals no difficulty completing any of the 24 activities. A score of 96 would indicate extreme difficulty with all activities.</description>
        <time_frame>Change from Day 0 to Day 56</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Infliximab</title>
            <description>Infliximab: the study drug will be injected into the joint through a needle</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Placebo: the placebo will be injected into the joint through a needle</description>
          </group>
          <group group_id="O3">
            <title>Methylprednisolone Acetate</title>
            <description>Standard of Care: Methylprednisolone acetate: Methylprednisolone acetate will be injected into the joint through a needle</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Western Ontario and McMaster Universities Arthritis Index (WOMAC) Score Target Knee</title>
          <description>The WOMAC questionnaire is used to evaluate the condition of patients with osteoarthritis. Patients answer questions based on how they are feeling. The questionnaire has a total of 24 questions which deal with pain, stiffness and physical function. Participants are asked to respond to how difficult it is for them to do/complete an activity. There is a total possible score of 96. A score of 0 equals no difficulty completing any of the 24 activities. A score of 96 would indicate extreme difficulty with all activities.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.9" spread="18.1"/>
                    <measurement group_id="O2" value="-9.3" spread="27.2"/>
                    <measurement group_id="O3" value="2.0" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Levels of Serum IL-6</title>
        <time_frame>Change from Day 0 to Day 56</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Infliximab</title>
            <description>Investigational (Infliximab) – 100mg The study drug will be injected into the joint through a needle</description>
          </group>
          <group group_id="O2">
            <title>Salt Water</title>
            <description>Placebo (Salt Water) – 10 ml Placebo solution will be injected into the joint through a needle</description>
          </group>
          <group group_id="O3">
            <title>Methylprednisolone Acetate</title>
            <description>Methylprednisolone Acetate (Standard of Care: MPA) – Standard of Care: MPA 80mg injected into the joint through a needle</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Levels of Serum IL-6</title>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="2.0"/>
                    <measurement group_id="O2" value="8.1" spread="13.0"/>
                    <measurement group_id="O3" value="5.5" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum CRP Day 0 to Day 56</title>
        <description>Serum measure of systemic inflammation</description>
        <time_frame>Day 0 to Day 56</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Infliximab</title>
            <description>Investigational (Infliximab) – 100mg The study drug will be injected into the joint through a needle</description>
          </group>
          <group group_id="O2">
            <title>Salt Water</title>
            <description>Placebo (Salt Water) – 10 ml Placebo solution will be injected into the joint through a needle</description>
          </group>
          <group group_id="O3">
            <title>Methylprednisolone Acetate</title>
            <description>Methylprednisolone Acetate (Standard of Care: MPA) – Standard of Care: MPA 80mg injected into the joint through a needle</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum CRP Day 0 to Day 56</title>
          <description>Serum measure of systemic inflammation</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.18" spread="0.37"/>
                    <measurement group_id="O2" value="-0.15" spread="0.30"/>
                    <measurement group_id="O3" value="0.08" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum SAA Levels Day 0 to Day 56</title>
        <description>Serum Amyloid A</description>
        <time_frame>Day 0 to Day 56</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Infliximab</title>
            <description>Investigational (Infliximab) – 100mg The study drug will be injected into the joint through a needle</description>
          </group>
          <group group_id="O2">
            <title>Salt Water</title>
            <description>Placebo (Salt Water) – 10 ml Placebo solution will be injected into the joint through a needle</description>
          </group>
          <group group_id="O3">
            <title>Methylprednisolone Acetate</title>
            <description>Methylprednisolone Acetate (Standard of Care: MPA) – Standard of Care: MPA 80mg injected into the joint through a needle</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum SAA Levels Day 0 to Day 56</title>
          <description>Serum Amyloid A</description>
          <units>ug/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="2256"/>
                    <measurement group_id="O2" value="-715.6" spread="1043"/>
                    <measurement group_id="O3" value="-1580.2" spread="4819"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Patients were observed for adverse events for 70 days (from screening (Day -14) through Day 56).</time_frame>
      <desc>Event information collected via subject reporting at visits.</desc>
      <group_list>
        <group group_id="E1">
          <title>Infliximab</title>
          <description>Investigational (Infliximab) – 100mg The study drug will be injected into the joint through a needle</description>
        </group>
        <group group_id="E2">
          <title>Salt Water</title>
          <description>Placebo (Salt Water) – 10 ml Placebo solution will be injected into the joint through a needle</description>
        </group>
        <group group_id="E3">
          <title>Methylprednisolone Acetate</title>
          <description>Methylprednisolone Acetate (Standard of Care: MPA) – Standard of Care: MPA 80mg injected into the joint through a needle</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pulled Muscle in Back</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pulling and Popping Sensation in Knee</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Swelling in Left Knee Following Biopsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain in Left knee</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain at Biopsy Site</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Twisted Left knee</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Herbert Lindsley</name_or_title>
      <organization>University of Kansas Medical Center</organization>
      <phone>(913) 588-3402</phone>
      <email>HLINDSLE@kumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

